Patents by Inventor Stephen P. Mayfield
Stephen P. Mayfield has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11578335Abstract: This invention provides synthetic promoters capable of promoting and/or initiating transcription of a polynucleotide in an algal cell, and methods of designing, producing and using such promoters.Type: GrantFiled: February 16, 2017Date of Patent: February 14, 2023Assignee: The Regents of the University of CaliforniaInventors: Stephen P. Mayfield, Melissa Scranton, David Ryan Georgianna, Joseph Ostrand, Anthony Jason Erich Berndt
-
Publication number: 20190382779Abstract: This invention provides synthetic promoters capable of promoting and/or initiating transcription of a polynucleotide in an algal cell, and methods of designing, producing and using such promoters.Type: ApplicationFiled: February 16, 2017Publication date: December 19, 2019Applicant: The Regents of the University of CaliforniaInventors: Stephen P. MAYFIELD, Melissa SCRANTON, David Ryan GEORGIANNA, Joseph OSTRAND, Anthony Jason Erich BERNDT
-
Patent number: 10047371Abstract: Provided are colostrum and milk polypeptides recombinantly expressed in photosynthetic organisms containing colostrum and milk polypeptides, compositions comprising such organisms and methods for producing such organisms.Type: GrantFiled: February 19, 2015Date of Patent: August 14, 2018Assignee: The Regents of the University of CaliforniaInventors: Stephen P. Mayfield, Beth A. Rasala, Miller Tran
-
Publication number: 20170342434Abstract: Provided are chloroplasts engineered to recombinantly express mammalian colostrum and milk polypeptides photosynthetic organisms containing such chloroplasts, and compositions comprising such organisms and methods for producing such organisms. In certain embodiments, provided is a chloroplast comprising one or more polynucleotides encoding one or more mammalian milk or colostrum polypeptides selected from osteopontin, lactadherin, cathelicidin-1, lysozyme, lactoperoxidase, lingual antimicrobial peptide (LAP), alpha-lactalbumin, and soluble CD14.Type: ApplicationFiled: August 11, 2017Publication date: November 30, 2017Applicant: The Regents of the University of CaliforniaInventors: Stephen P. MAYFIELD, Austin HALLGREN, Beth A. RASALA, Miller TRAN, Michael MAYFIELD
-
Patent number: 9732351Abstract: Provided are chloroplasts engineered to recombinantly express mammalian colostrum and milk polypeptides, photosynthetic organisms containing such chloroplasts, and compositions comprising such organisms and methods for producing such organisms. In certain embodiments, provided is a chloroplast comprising one or more polynucleotides encoding one or more mammalian milk or colostrum polypeptides selected from osteopontin, lactadherin, cathelicidin-1, lysozyme, lactoperoxidase, lingual antimicrobial peptide (LAP), alpha-lactalbumin, and soluble CD14.Type: GrantFiled: April 22, 2016Date of Patent: August 15, 2017Assignee: The Regents of the University of CaliforniaInventors: Stephen P. Mayfield, Austin Hallgren, Beth A. Rasala, Miller Tran, Michael Mayfield
-
Publication number: 20170015745Abstract: Methods and compositions are disclosed to engineer chloroplast comprising heterologous genes encoding target binding domain fused to a eukaryotic toxin and produced within a subcellular organelle, such as a chloroplast. The present disclosure demonstrates that when chloroplasts are used, toxins normally refractive to production in eukaryotic cells may be used to produce recombinant fusion proteins with binding domains that are soluble, properly folded and post-translationally modified, where the multifunctional activity of the fusion protein is intact. The binding domains may include those from antibodies, receptors, hormones, cytokines, chemokines, and interferons. The present disclosure also demonstrates the utility of plants, including green algae, for the production of complex multi-domain proteins as soluble bioactive therapeutic agents.Type: ApplicationFiled: July 5, 2016Publication date: January 19, 2017Inventors: Stephen P. Mayfield, Miller Tran
-
Publication number: 20170009250Abstract: The present disclosure relates to methods of expressing therapeutic proteins in photosynthetic organisms and the therapeutic proteins produced by the methods. The therapeutic proteins include high-mobility group box 1 (HMGB1) protein, fibronectin domain (10) (10FN3), fibronectin domain (14) (14FN3), interferon beta (IFN?), proinsulin and vascular endothelial growth factor (VEGF). The photosynthetic organisms include prokaryotes such as cyanobacteria and eukaryotes such as alga and plants. Transformation of eukaryotes is preferably the plastid genome, more preferably the chloroplast genome.Type: ApplicationFiled: January 28, 2016Publication date: January 12, 2017Applicants: Sapphire Energy, Inc., The Scripps Research InstituteInventors: Beth A. Rasala, Rosa M. F. Cardoso, Machiko Muto, Stephen P. Mayfield, Philip A. Lee, Craig A. Behnke, Michael Mendez
-
Publication number: 20160369291Abstract: Provided are colostrum and milk polypeptides recombinantly expressed in photosynthetic organisms containing colostrum and milk polypeptides, compositions comprising such organisms and methods for producing such organisms.Type: ApplicationFiled: February 19, 2015Publication date: December 22, 2016Applicant: The Regents of the University of CaliforniaInventors: Stephen P. MAYFIELD, Beth A. RASALA, Miller TRAN
-
Publication number: 20160257730Abstract: Provided are colostrum and milk polypeptides recombinantly expressed in photosynthetic organisms containing colostrum and milk polypeptides, compositions comprising such organisms and methods for producing such organisms.Type: ApplicationFiled: April 22, 2016Publication date: September 8, 2016Applicant: The Regents of the University of CaliforniaInventors: Stephen P. MAYFIELD, Austin HALLGREN, Beth A. RASALA, Miller TRAN, Michael MAYFIELD
-
Patent number: 9422347Abstract: The present invention relates to the production of malaria transmission blocking vaccines in single-celled green algae, particularly algae of the genus Chlamydomonas, e.g., Chlamydomonas reinhardtii; the immunogenic Plasmodium polypeptides produced and compositions comprising them; and methods for preventing, ameliorating, reducing, delaying, treating and blocking the transmission of malaria by administration of immunogenic Plasmodium polypeptides produced in an algal host cell.Type: GrantFiled: May 1, 2012Date of Patent: August 23, 2016Assignee: The Regents of the University of CaliforniaInventors: Stephen P. Mayfield, James A. Gregory, Carla S. Jones, Michael J. Hannon
-
Patent number: 8932576Abstract: Methods and compositions are disclosed to engineer chloroplast comprising heterologous mammalian genes via a direct replacement of chloroplast Photosystem II (PSII) reaction center protein coding regions to achieve expression of recombinant protein above 5% of total protein. When algae is used, algal expressed protein is produced predominantly as a soluble protein where the functional activity of the peptide is intact. As the host algae is edible, production of biologics in this organism for oral delivery of proteins/peptides, especially gut active proteins, without purification is disclosed.Type: GrantFiled: January 27, 2010Date of Patent: January 13, 2015Assignee: The Scripps Research InstituteInventor: Stephen P. Mayfield
-
Publication number: 20140219971Abstract: The present invention relates to the production of malaria transmission blocking vaccines in single-celled green algae, particularly algae of the genus Chlamydomonas, e.g., Chlamydomonas reinhardtii; the immunogenic Plasmodium polypeptides produced and compositions comprising them; and methods for preventing, ameliorating, reducing, delaying, treating and blocking the transmission of malaria by administration of immunogenic Plasmodium polypeptides produced in an algal host cell.Type: ApplicationFiled: May 1, 2012Publication date: August 7, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Stephen P. Mayfield, James A. Gregory, Carla S. Jones, Michael J. Hannon
-
Publication number: 20120309939Abstract: The present disclosure relates to methods of expressing therapeutic proteins in photosynthetic organisms and the therapeutic proteins produced by the methods. The therapeutic proteins include high-mobility group box 1 (HMGB1) protein, fibronectin domain (10) (10FN3), fibronectin domain (14) (14FN3), interferon beta (IFN?), proinsulin and vascular endothelial growth factor (VEGF). The photosynthetic organisms include prokaryotes such as cyanobacteria and eukaryotes such as alga and plants. Transformation of eukaryotes is preferably the plastid genome, more preferably the chloroplast genome.Type: ApplicationFiled: November 19, 2010Publication date: December 6, 2012Applicants: THE SCRIPPS RESEARCH INSTITUTE, SAPPHIRE ENERGY, INC.Inventors: Beth A. Rasala, Rosa M. F. Cardoso, Machiko Muto, Stephen P. Mayfield, Philip A. Lee, Craig A. Behnke, Michael Mendez
-
Publication number: 20100129394Abstract: Methods and compositions are disclosed to engineer chloroplast comprising heterologous mammalian genes via a direct replacement of chloroplast Photosystem II (PSII) reaction center protein coding regions to achieve expression of recombinant protein above 5% of total protein. When algae is used, algal expressed protein is produced predominantly as a soluble protein where the functional activity of the peptide is intact. As the host algae is edible, production of biologics in this organism for oral delivery of proteins/peptides, especially gut active proteins, without purification is disclosed.Type: ApplicationFiled: January 27, 2010Publication date: May 27, 2010Inventor: Stephen P. Mayfield
-
Patent number: 7678561Abstract: Methods and compositions are disclosed to engineer chloroplast comprising heterologous mammalian genes via a direct replacement of chloroplast Photosystem II (PSII) reaction center protein coding regions to achieve expression of recombinant protein above 5% of total protein. When algae is used, algal expressed protein is produced predominantly as a soluble protein where the functional activity of the peptide is intact. As the host algae is edible, production of biologics in this organism for oral delivery or proteins/peptides, especially gut active proteins, without purification is disclosed.Type: GrantFiled: May 9, 2007Date of Patent: March 16, 2010Assignee: The Scripps Research InstituteInventor: Stephen P. Mayfield
-
Publication number: 20090148904Abstract: Methods and compositions are disclosed to engineer chloroplast comprising heterologous genes encoding target binding domain fused to a eukaryotic toxin and produced within a subcellular organelle, such as a chloroplast. The present disclosure demonstrates that when chloroplasts are used, toxins normally refractive to production in eukaryotic cells may be used to produce recombinant fusion proteins with binding domains that are soluble, properly folded and post-translationally modified, where the multifunctional activity of the fusion protein is intact. The binding domains may include those from antibodies, receptors, hormones, cytokines, chemokines, and interferons. The present disclosure also demonstrates the utility of plants, including green algae, for the production of complex multi-domain proteins as soluble bioactive therapeutic agents.Type: ApplicationFiled: November 12, 2008Publication date: June 11, 2009Inventor: Stephen P. Mayfield
-
Publication number: 20040014174Abstract: Methods of producing one or more polypeptides in a plant chloroplast, including methods of producing polypeptides that specifically associate in a plant chloroplast to generate a functional protein complex, are provided. An isolated polynucleotide that includes (or encodes) a first ribosome binding sequence (RBS) operatively linked to a second RBS, such that the first RBS directs translation of a polypeptide in a prokaryote and the second RBS directs translation of the polypeptide in a chloroplast, also is provided, as is a vector containing such a polynucleotide, particularly a chloroplast vector and a chloroplast/prokaryote shuttle vector. Also provided is a synthetic polynucleotide, which is chloroplast codon biased. A plant cell that is genetically modified to contain a polynucleotide or vector as described above, as well as transgenic plants containing or derived from such a genetically modified cell, are provide. Polypeptides encoded by a synthetic polynucleotide as described also are provided.Type: ApplicationFiled: April 23, 2003Publication date: January 22, 2004Inventors: Stephen P. Mayfield, Scott Franklin
-
Patent number: RE39350Abstract: The present invention relates to a gene expression system in eukaryotic and prokaryotic cells, preferably plant cells and intact plants. In particular, the invention relates to an expression system having a RB47 binding site upstream of a translation initiation site for regulation of translation mediated by binding of RB47 protein, a member of the poly(A) binding protein family. Regulation is further effected by RB60, a protein disulfide isomerase. The expression system is capable of functioning in the nuclear/cytoplasm of cells and in the chloroplast of plants. Translation regulation of a desired molecule is enhanced approximately 100 fold over that obtained without RB47 binding site activation.Type: GrantFiled: January 16, 1998Date of Patent: October 17, 2006Assignee: The Scripps Research InstituteInventor: Stephen P. Mayfield
-
Patent number: RE44266Abstract: The present invention relates to a gene expression system in eukaryotic and prokaryotic cells, preferably plant cells and intact plants. In particular, the invention relates to an expression system having a RB47 binding site upstream of a translation initiation site for regulation of translation mediated by binding of RB47 protein, a member of the poly(A) binding protein family. Regulation is further effected by RB60, a protein disulfide isomerase. The expression system is capable of functioning in the nuclear/cytoplasm of cells and in the chloroplast of plants. Translation regulation of a desired molecule is enhanced approximately 100 fold over that obtained without RB47 binding site activation.Type: GrantFiled: January 16, 1998Date of Patent: June 4, 2013Assignee: The Scripps Research InstituteInventor: Stephen P. Mayfield